All In Biotech

Drug Trial Radar · NCT04059406

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients With Non-Transfusion Dependent β-Thalassemia Intermedia

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

29

Actual

Start

Sep 24, 2020

Primary completion

Mar 28, 2023

Study completion Mar 28, 2023

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Aug 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose was to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of sapablursen administered subcutaneously to participants with non-transfusion dependent β-Thalassemia Intermedia.

Conditions

  • Beta Thalassemia Intermedia

Interventions

  • sapablursenDrug

    sapablursen administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27Time frame: Baseline and Week 27

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Aghia Sophia General Children's Hospital

    Athens, Attica, Greece

  • University General Hospital of Patras

    Patra, Peloponnese, Greece

  • Koutlimbaneio & Triantafylleio General Hospital of Larissa

    Larissa, Thessaly, Greece

  • Chronic Care Center

    Hazmiyeh, Lebanon

  • Siriraj Hospital

    Bangkok, Thailand

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, Thailand

  • Srinagarind Hospital

    Khon Kaen, Thailand

  • Thammasat University Hospital

    Pathum Thani, Thailand

  • King Chulalongkorn Memorial Hospital

    Pathum Wan, Thailand

  • Naresuan University Hospital

    Phitsanulok, Thailand

  • Songklanagarind Hospital

    Songkhla, Thailand

  • Cukurova Üniversitesi Tıp Fakültesi

    Adana, Turkey (Türkiye)

  • Hacettepe Üniversitesi Tıp Fakültesi

    Ankara, Turkey (Türkiye)

  • Akdeniz University Faculty of Medicine

    Antalya, Turkey (Türkiye)

  • Ege Universitesi Tip Fakultesi

    Izmir, Turkey (Türkiye)

  • İstanbul Üniversitesi - Istanbul Tıp Fakültesi

    Topkapı, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.